Monopar Therapeutics Inc.
HealthcareNASDAQ:MNPR · NASDAQ Capital Market
+$0.68 today
Vol 0.15M · Avg 0.18M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-10.0%
avg -63.6%
ROIC
-12.1%
avg -64.8%
ROA
-9.7%
avg -56.3%
Analysis
ROA is currently the strongest return metric at -9.7% versus its period average of -56.3%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Chandler D. Robinson | Co-Founder, Chief Executive Officer, President & Director | $1.67M | — | 42 | $106,276.00 | 1.59% |
Andrew J. Cittadine | Chief Operating Officer | $985,000.00 | — | 54 | $54,240.00 | 0.81% |
Quan Anh Vu | CFO, Principal accounting officer, Principal financial officer, Secretary & Treasurer | $623,506.00 | — | 54 | $1,500.00 | 0.02% |
Christopher Starr | Co-Founder & Independent Executive Chairman of the Board | $200,000.00 | — | 74 | $2,924.00 | 0.04% |
Susan Rodriguez | Chief Commercial & Strategy Officer | — | — | 64 | $0.00 | <0.01% |
Patrice Rioux | Acting Chief Medical Officer | — | — | 75 | $2,000.00 | 0.03% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
1
$104,925.00
Sells
6
$37.04M
Net Sentiment
$36.94M
Net selling
Most Active
KLAUSNER ARTHUR J
2 transactions
Analysis
Insiders reported 1 buys worth $104,925.00 and 6 sells worth $37.04M over the last 12 months. That adds up to net selling of $36.94M. KLAUSNER ARTHUR J was the most active insider with 2 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | N/A | N/A6 analysts |
| Net Income | N/A | N/A | N/A | N/A6 analysts |
| EBIT | N/A | N/A | N/A | N/A6 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
KalVista Pharmaceuticals, Inc.
NASDAQ:KALV
$1.44B
Lexicon Pharmaceuticals, Inc.
NASDAQ:LXRX
$852.86M
Omeros Corporation
NASDAQ:OMER
$632.20M
4D Molecular Therapeutics, Inc.
NASDAQ:FDMT
$461.60M
Neumora Therapeutics, Inc. Common Stock
NASDAQ:NMRA
$329.81M
Bicycle Therapeutics plc
NASDAQ:BCYC
$281.05M
Compass Therapeutics, Inc.
NASDAQ:CMPX
$280.72M
Akebia Therapeutics, Inc.
NASDAQ:AKBA
$248.00M
Fulcrum Therapeutics, Inc.
NASDAQ:FULC
$186.68M
Gossamer Bio, Inc.
GOSS
$38.00M
Who manages MNPR?
Monopar Therapeutics Inc. (MNPR) lists 6 active executives. The top listed executive is Chandler D. Robinson, Co-Founder, Chief Executive Officer, President & Director.
Are MNPR insiders buying or selling?
Recent insider activity shows net selling of $26.39M.
Explore More
Continue the stock analysis
Jump to another research area for this company.